Generic Boniva Gets FDA OK
WASHINGTON -- The FDA has approved the first generic versions of ibandronate (Boniva) tablets for the once-a-month treatment or prevention of osteoporosis after menopause.
Approval was granted to Apotex, Orchid Healthcare, and Mylan Pharmaceuticals to market 150 mg generic ibandronate tablets, the agency said in a statement.
Patients receiving the generics will get a medication guide listing the adverse events related to use of the drug, including esophageal problems, low blood-calcium levels, unusual thigh bone fractures, and other bone, joint, and muscle pain.
Common adverse events include back pain, dyspepsia, extremity pain, diarrhea, headache, and myalgia.
A recent European trial showed that by 21%, yet the USPSTF recommends against routine PSA testing.
MedPage Today® surveys are polls of those who choose to participate and are, therefore, not valid statistical samples, but rather a snapshot of what your colleagues are thinking
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
This Site and third parties who place advertisements on this Site may collect and use information about your visits to this Site and other websites in order to provide advertisements about goods and services of interest to you.
If you would like to obtain more information about these advertising practices and to make choices about online behavioral advertising, please